PharmEnable Therapeutics
PrivateLast Round
Early Funding
May 22, 2023
Total Funding Raised
$9.73M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
PharmEnable Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was an Early Funding round in May 2023.
PharmEnable Therapeutics is a biotechnology company that leverages artificial intelligence and advanced medicinal chemistry to discover and develop novel small molecule therapeutics for challenging disease targets in oncology and neurology.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PharmEnable Therapeutics Comparables
Compare PharmEnable Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aqemia | 84% | |
| Genesis Molecular AI | 82% | |
| Charm Therapeutics | 81% |
For institutional investors. Book with your work email.
PharmEnable Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | May 22, 2023 | ||||
| Seed | Jun 30, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
PharmEnable Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| KQ Labs | Seed |
| MP Healthcare Venture Management | Early Funding |
| o2h ventures | Early Funding |
| Cambridge Enterprise | Early Funding, Seed |
| Parkwalk Advisors | Early Funding, Seed |
| Wren Capital | Early Funding, Seed |
| Martlet Capital | Early Funding, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 683% MoM, from 188 to 1.5K.
- Jun 30, 2020
$2.23M round led by Cambridge Enterprise.
For institutional investors. Book with your work email.
PharmEnable Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about PharmEnable Therapeutics's valuation, stock price, and market status.
Is PharmEnable Therapeutics a public or private company?
PharmEnable Therapeutics is a private company.
What is the current stock price of PharmEnable Therapeutics?
PharmEnable Therapeutics is a private company, so its shares have no public market price. Caplight tracks PharmEnable Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is PharmEnable Therapeutics worth (valuation)?
Valuation information for PharmEnable Therapeutics is not publicly available.
Can I buy PharmEnable Therapeutics stock?
PharmEnable Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was PharmEnable Therapeutics's last funding round?
PharmEnable Therapeutics's most recent funding round was Early Funding on May 22, 2023.
Who are the main investors in PharmEnable Therapeutics?
Key investors in PharmEnable Therapeutics include MP Healthcare Venture Management, Cambridge Enterprise.
Will PharmEnable Therapeutics IPO soon?
No public IPO plans have been announced for PharmEnable Therapeutics.
How can I track PharmEnable Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in PharmEnable Therapeutics's shares on secondary markets.